CALT - Calliditas' partner Everest gets review of kidney disease drug Nefecon in China

• Calliditas Therapeutics ( OTCPK:CLTEF ) ( NASDAQ: CALT ) said China's National Medical Products Administration (NMPA) accepted to review Everest Medicines' new drug application (NDA) for kidney disease drug Nefecon.
• Calliditas said that Nefecon, if approved, will be the first-ever approved therapeutic option indicated for primary IgAN treatment in China.
• In March, Calliditas said Everest had filed the NDA to the NMPA for Nefecon to treat treat IgA Nephropathy — a disease which occurs when an antibody called immunoglobulin A (IgA) builds up in the kidneys. This leads to inflammation which can hamper the kidneys' ability to filter waste from the blood.
• Nefecon is sold as Tarpeyo in the U.S. and as Kinpeygo in the EU .
• Calliditas noted that it has a license agreement with Everest to develop and commercialize Nefecon in Greater China, Singapore and South Korea in IgAN.

For further details see: